Education
About Us
Working with TipRanks
Follow Us
Genmab A/S (GMAB)
NASDAQ:GMAB
GMAB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$17.24 - $33.61
Previous CloseN/A
Volume229.76K
Average Volume (3M)1.89M
Market Cap
$20.30B
Enterprise Value$9.96B
Total Cash (Recent Filing)$18.37B
Total Debt (Recent Filing)$937.88M
Price to Earnings (P/E)16.6
Beta0.51
Next Earnings
Nov 06, 2025EPS Estimate
0.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.54
Shares Outstanding642,063,500
10 Day Avg. Volume2,710,436
30 Day Avg. Volume1,892,471
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.49
Enterprise Value/Revenue0.44
Enterprise Value/Gross Profit0.46
Enterprise Value/Ebitda1.30
Forecast
1Y Price Target
$39.60Price Target Upside18.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Bulls Say, Bears Say
Bulls Say
Acquisition BenefitsThe acquisition of Merus accelerates Genmab's shift from a royalty to a wholly owned model with long-term growth potential.
Market OpportunityPetosemtamab's market opportunity in head and neck cancer alone could exceed $3B annually.
Pipeline GrowthGenmab's late-stage pipeline has the potential for over $8 billion in annual revenue, bolstered by promising assets like Epkinly and Rina-S.
Bears Say
Debt ConcernsConcerns exist regarding the debt required to complete the Merus acquisition, influencing the current flat trading of Genmab shares.
Financial BurdenThe $8B deal is sizable and carries significant operating expenses and interest expense dilution in the initial years following the acquisition.
Genmab News
GMAB FAQ
What was Genmab A/S’s price range in the past 12 months?
Genmab A/S lowest stock price was $17.23 and its highest was $33.61 in the past 12 months.
What is Genmab A/S’s market cap?
Genmab A/S’s market cap is $20.30B.
When is Genmab A/S’s upcoming earnings report date?
Genmab A/S’s upcoming earnings report date is Nov 06, 2025 which is in 30 days.
How were Genmab A/S’s earnings last quarter?
Genmab A/S released its earnings results on Aug 07, 2025. The company reported $0.542 earnings per share for the quarter, beating the consensus estimate of $0.399 by $0.143.
Is Genmab A/S overvalued?
According to Wall Street analysts Genmab A/S’s price is currently Undervalued.
Does Genmab A/S pay dividends?
Genmab A/S does not currently pay dividends.
What is Genmab A/S’s EPS estimate?
Genmab A/S’s EPS estimate is 0.47.
How many shares outstanding does Genmab A/S have?
Genmab A/S has 642,063,500 shares outstanding.
What happened to Genmab A/S’s price movement after its last earnings report?
Genmab A/S reported an EPS of $0.542 in its last earnings report, beating expectations of $0.399. Following the earnings report the stock price went up 5.486%.
Which hedge fund is a major shareholder of Genmab A/S?
Currently, no hedge funds are holding shares in GMAB
Genmab Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$39.60 (18.00% Upside)
$39.60 (18.00% Upside)
Blogger Sentiment
Bullish
GMAB Sentiment 66%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 425.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 9.2%
Last 30 Days ▲ 9.1%
Last 30 Days ▲ 9.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
43.41%
12-Months-Change
Fundamentals
Return on Equity
26.08%
Trailing 12-Months
Asset Growth
16.47%
Trailing 12-Months
Company Description
Genmab A/S
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company's also develops products, which is in Phase 2 comprise Teclistamab for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
GMAB Company Deck
GMAB Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong financial performance and promising clinical trial results, particularly for EPKINLY and Rina-S. The company is strategically investing in its pipeline and expanding its market presence. However, challenges such as the discontinuation of HexaBody-OX40 and potential regulatory hurdles were noted.View all GMAB earnings summariesGMAB Stock 12 Month Forecast
Average Price Target
$39.60
▲(18.00% Upside)
Technical Analysis
Ownership Overview
―
Insiders
0.89% Mutual Funds
2.96% Other Institutional Investors
95.34% Public Companies and Individual Investors